STADA to acquire FERN C portfolio in the Philippines

Share on facebook
Share on google
Share on twitter
Share on linkedin
Share on pinterest
Taguig City, February 7, 2020 – After announcing a number of acquisitions and partnerships in Europe recently, the STADA Group is also expanding its portfolio in the Asia-Pacific region. As the global manufacturer of high-quality generic drugs and consumer healthcare products announced today, STADA is acquiring the FERN portfolio in the Philippines, one of the leading brands in the growing local Vitamin C market.The product range consists of FERN-C, a Vitamin C product that has been in the market for 15 years and FERN-C Kidz and Kiddimin – two products for the vitamin supply for children.
fernc vitamins

Memorandum of Agreement signing between Fern CEO, Tommany Tan, and STADA Philippines’ General Manager, Sharmaine Abarientos

STADA to acquire an established OTC portfolio in the Philippines
  • STADA’s Philippine portfolio is being strengthened with FERN C, a well-established range of food supplements.
  • STADA Philippines General Manager Sharmaine Abarientos: “With FERN C in our portfolio, we will establish a strong consumer healthcare platform to launch other quality medicines as well and provide better health for all Filipinos.”
  • STADA CEO Peter Goldschmidt: “The acquisition of FERN will help us to execute our growth ambitions in the Philippines.”
  • STADA Asia Pacific Managing Director Gary Clark: “With both STADA and FERN carrying heritage, we will be able to provide better health for Filipinos.“
STADA has a long lasting history of selling pharmaceutical products into the Philippines, formerly through Croma Medic Inc. which was required by STADA in [early 2000] and recently renamed into STADA Philippines. 
“After having formally launched STADA Philippines, we are now fully enabled to execute our growth ambitions in this market as well. The acquisition of FERN will help us to succeed. The acquisition of these products is in line with our strategy to strengthen our portfolio with well-established consumer healthcare brands and also expand in selected emerging markets”, states STADA CEO Peter Goldschmidt. 
STADA has been helping people by making high quality products. That is why STADA is always on the lookout for acquisitions and partnerships. With the acquisition of these established brands, it will further STADA’s vision to be a trusted partner that provides high-quality, holistic care for the people. With both STADA and FERN carrying heritage, we will be able to provide better health for Filipinos“, declares STADA Asia Pacific Managing Director Gary Clark. 
Sharmaine Abarientos, General Manager of STADA Philippines, adds: “FERN has not only an established brand heritage, but also a complete range for adults as well as for the pediatric application. With FERN in our portfolio, we will establish a strong consumer healthcare platform to launch other quality medicines as well and provide better health for all Filipinos. With our successful portfolio expansion activities, we are able to offer quality medicines at reasonable prices, across all segments of healthcare; specialty, generics and consumer health.”
About STADA Arzneimittel AGSTADA Arzneimittel AG is headquartered in Bad Vilbel, Germany. The company focuses on a two pillar strategy consisting of generics, including specialty pharmaceuticals and non-prescription consumer health products. Worldwide, STADA Arzneimittel AG sells its products in approximately 120 countries. In financial year 2018, STADA achieved adjusted Group sales of EUR 2,330.8 million and adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) of EUR 503.5 million. As of December 31, 2018, STADA employed 10,416 people worldwide.
Additional information for journalists:
STADA Arzneimittel AG / Media Relations / Stadastrasse 2-18 / 61118 Bad Vilbel – Germany 
Phone: +49 (0) 6101 603-165 / Fax: +49 (0) 6101 603-215 / E-Mail: press@stada.de
Or visit us on the Internet at www.stada.com/press
Additional information for capital market participants:
STADA Arzneimittel AG / Investor & Creditor Relations / Stadastrasse 2-18 / 61118 Bad Vilbel – Germany / Phone: +49 (0) 6101 603-4689 / Fax: +49 (0) 6101 603-215 / E-mail: ir@stada.de
Or visit us on the Internet at www.stada.com/investor-relations

sherfriends

sherfriends

Leave a Replay